Elexacaftor–tezacaftor–ivacaftor (ETI) was approved by the US Food and Drug Administration (FDA) for adolescents and adults with CF and ≥1 copy of the F508del variant in the CFTR gene at the end of 2019. The gene discussed is CFTR; the disease is cystic fibrosis.